Okay, here’s a breakdown of the provided text, focusing on key facts and potential implications for pharmacists:
Key Takeaways:
* Enlicitide Decanoate: This drug is a potential first-in-class oral PCSK9 inhibitor being developed for cholesterol reduction. It recently received a National Priority voucher from the FDA.
* PCSK9 Inhibitors & Current Landscape: Statins are still the first-line treatment for high cholesterol. However, manny patients don’t reach thier LDL-C goals with statins alone. Currently, PCSK9 inhibitors are available, but they are injectable.
* Potential Benefits of Oral Formulation: An oral PCSK9 inhibitor like enlicitide could:
* Reduce Clinical Inertia: Doctors might be more likely to prescribe an oral medication than an injectable one.
* Improve Patient Adherence: Oral medications are generally easier for patients to take consistently.
* Pharmacist’s Role:
* Counseling: pharmacists will be crucial in educating patients about proper administration:
* Take enlicitide first thing in the morning on an empty stomach.
* Monitoring: Pharmacists should help identify eligible patients and ensure routine LDL-C monitoring to assess effectiveness.
* CORALreef Lipids Trial: This trial showed enlicitide achieved nearly a 60% reduction in LDL-C when added to existing background therapy. This efficacy is comparable to injectable PCSK9 mAbs.
* Expert Opinion (Ann Marie Navar, MD, PhD): Enlicitide is a valuable option for patients who don’t reach their cholesterol goals with statins alone.
In essence, this article highlights a potentially significant advancement in cholesterol management – a convenient oral PCSK9 inhibitor – and emphasizes the vital role pharmacists will play in its successful implementation.
